Argenx
ARGX
#469
Rank
S$69.41 B
Marketcap
S$1,109
Share price
0.12%
Change (1 day)
34.98%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): S$20.50

According to Argenx 's latest financial reports the company's current EPS (TTM) is S$20.25. In 2025 the company made an earnings per share (EPS) of S$27.00 an increase over its 2024 EPS that were of S$17.83.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$20.50-24.07%
2025S$27.0051.44%
2024S$17.83-369.77%
2023S-$6.61-60.46%
2022S-$16.7263.33%
2021S-$10.24-40.37%
2020S-$17.17183.47%
2019S-$6.06123.09%
2018S-$2.7154.93%
2017S-$1.7514.07%
2016S-$1.5413.05%
2015S-$1.36-36.34%
2014S-$2.13209.04%
2013S-$0.69-33.99%
2012S-$1.05185.59%
2011S-$0.37